Proven
neurotechnology
built for the
real world
Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication.
Proven
neurotechnology
built for the
real world
Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication.
Capability
From signal to actionable insight
The Control Bionics neural-signal platform captures physiological data with medical-grade precision and converts it into measurable, decision-ready outcomes. Built for deployment across clinical, research, and performance environments — and validated where it counts.
Signal acquisition and processing
Real-time analysis and validation
Clinical integration and reporting
Technology
The platform serves distinct markets with precision and measurable outcomes. One underlying technology - four applications.
A platform built for clinical deployment
Medical-grade signal processing meets real-world clinical environments. Designed for integration, validation, and measurable outcomes.
Non-invasive neural signal capture
Physiological data without surgical intervention or implantation. Validated for use in complex clinical environments.
Regulatory pathway established
Cleared for clinical use with ongoing validation across multiple applications — FDA, TGA, and CE registered.
Outcome-focused architecture
Platform designed to deliver decision-ready insights, not only raw data. Built to integrate into clinical and research workflows.
Evidence from clinical and research deployment
Control Bionics technology is validated through research, clinical trials, and real-world deployment across rehabilitation, performance, and research settings.
1,000s of users
Trusted by individuals, clinicians, and organisations across four markets
Government and privately funded
Approved for funding through Medicare, Medicaid, NDIS, and private insurance pathways.
100%
Non-invasive signal acquisition
3 Regulatory clearances
(FDA, TGA, CE)
Latest from our platform
Research, clinical validation and platform developments.
Control Bionics has “Fascinating Technology” According to NPR’s Cool Science Radio
Control Bionics CTO, James Schorey, and Sales Director, Meagan Koeneman, talked to NPR’s Cool Science Radio about the technology behind the NeuroNode Trilogy, who benefits from these products, and the importance of communication at the human level.
Popular Podcast, Fear and Greed, Spoke to Control Bionics on Their Sunday Feature
Control Bionics CEO Rob Wong sat down with the podcast Fear and Greed this week to discuss how Control Bionics helps patients with some of the most debilitating conditions to communicate.
Biotech Daily features Control Bionics in Dr. Boreham’s Crucible Article
As a regular contributor of Biotech Daily, which provides news on ASX-listed biotechnology companies, Dr. Boreham’s Crucible provides analysis of the biotech sector in Australia. Last week Control Bionics was featured in an article on the site.
Control Bionics (ASX:CBL) Looks to Solidify Global Presence
Rob-Wong-Alan-Kohler-–-Eureka-Report Rob Wong, CEO of Control Bionics, chats with Alan Kohler from Eureka Report to discuss the latest news from the newly ASX-listed business. " … the fundamental point about that was that your brain sends very, very fast signals to...
Select your path to neural-signal insights and outcomes
Explore how the platform integrates into clinical workflows and delivers decision-ready outcomes.
Learn more
Discover how researchers are using real-time neural data to power breakthrough studies.
LearnNDIS-registered provider
Control Bionics is a registered NDIS provider. Eligible participants can access our assistive communication devices and neurotechnology solutions through their NDIS plan.